Tango rises after Q4 results, clinical pact with Erasca
Source: SeekingAlpha
2026-03-05 13:46:18 ET
More on Tango Therapeutics, Erasca
- Tango Therapeutics, Inc. (TNGX) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Tango Therapeutics, Inc. (TNGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Erasca, Inc. (ERAS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Erasca prices $225M stock offering at $10 per share
- Seeking Alpha’s Quant Rating on Tango Therapeutics
Read the full article on Seeking Alpha
For further details see:
Tango rises after Q4 results, clinical pact with Erasca
Erasca Inc.
NASDAQ: ERAS
ERAS Trading
3.1% G/L:
$15.95 Last:
1,936,895 Volume:
$15.755 Open:
ERAS Latest News
March 10, 2026 08:00:00 am
Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau
March 05, 2026 07:01:00 am
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat
February 24, 2026 08:00:00 am
Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001
ERAS Stock Data
$3,659,231,070
262,117,305
1.32%
40
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
